SELECTIVE ACTIVATION OF ANTIFUNGAL PRODRUGS
DESCRIPTION (Provided by applicant): The proposed research will investigate the
feasibility of utilizing inherent properties of the infection site as a means
to activate antifungal prodrugs selectively. Prodrug derivatives of an
antifungal agent will be prepared and tested for their susceptibility to
activation by conditions present at infection sites of C. albicans. Test
compounds will be analyzed both in vitro and in vivo to determine their
selectivity for the fungal infection. Promising leads will be those compounds
which are both easily activated by these conditions and are resistant to
activation in the normal mammalian physiological environment. Phase II will
optimize the prodrug design based on our lead candidates and take this second
generation design into preclinical testing.
Small Business Information at Submission:
HAWAII BIOTECH, INC.
HAWAII BIOTECH, INC. 99-193 AIEA HEIGHTS DR, STE 236 AIEA, HI 96701
Number of Employees: